Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07302347CT.gov A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) | — | Recruiting | — | — | — |
NCT06475235CT.gov Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL | — | Recruiting | — | — | — |
NCT06137144CT.gov AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. | — | Recruiting | — | — | — |
NCT05878691CT.gov A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. | — | Active Not Recruiting | — | — | — |
NCT05296772CT.gov Phase 1 First-in-human Study of JS014 | — | Unknown | — | — | — |
NCT04920383CT.gov ALPN-202 With PD-1 Inhibition in Advanced Malignancies | — | Terminated | — | — | — |
NCT04609579CT.gov Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | — | Terminated | — | — | — |
NCT03983668CT.gov CMP-001 for Relapsed and Refractory Lymphoma | — | Terminated | — | — | — |
NCT03990961CT.gov Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | — | Terminated | — | — | — |
NCT03995147CT.gov Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | — | Active Not Recruiting | — | — | — |
Show 16 more trialsShow fewer
NCT03829254CT.gov A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | — | Recruiting | — | — | — |
NCT03934814CT.gov Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | — | Completed | — | — | — |
NCT03884556CT.gov TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | — | Completed | — | — | — |
NCT03586024CT.gov Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas | — | Withdrawn | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03815682CT.gov RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | — | Terminated | — | — | — |
NCT03255018CT.gov Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | — | Completed | — | — | — |
NCT03316573CT.gov Pembrolizumab in Neoplasms or Lymphomas | — | Suspended | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03249792CT.gov Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) | — | Terminated | — | — | — |
NCT03179930CT.gov Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas | — | Active Not Recruiting | — | — | — |
NCT03010176CT.gov Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | — | Completed | — | — | — |
NCT02408042CT.gov Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | — | Withdrawn | — | — | — |
NCT02332668CT.gov A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | — | Recruiting | — | — | — |
NCT02376699CT.gov Safety Study of SEA-CD40 in Cancer Patients | — | Terminated | — | — | — |
NCT01986426CT.gov LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Merck Sharp & Dohme LLC | P2 | B · 56 |
| Vinblastine | Intensity Therapeutics, Inc. | P4 | BBB |
| Prednisolone | The Lymphoma Academic Research Organisation | P4 | BBB |
| Cyclophosphamide | Beth Israel Deaconess Medical Center | P4 | BB |
| Vincristine Sulfate | Inhye Ahn | P3 | BB |
| Bleomycin | Shandong Provincial Hospital | P4 | BB |
| Methotrexate | University of Chicago | P4 | BB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Isocyclophosphamide | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | P3 | BB |
+42 more in the Lymphoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →